# Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)

> **NCT07264166** · — · ENROLLING_BY_INVITATION · sponsor: **Healing Hope International** · enrollment: 25 (estimated)

## Conditions studied

- Hypoxic Brain Damage
- Hypoxic Ischaemic Encephalopathy (HIE)
- Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest
- Hypoxic Ischemic Encephalopathy of Newborn
- Cerebral Palsy
- Cerebral Palsy (CP)
- Cerebral Palsy Hemiparetic Cerebral Palsy Spasticity Gait Disorders, Neurologic Postural Balance Impairment
- Cerebral Palsy Quadriplegic
- Cerebral Palsy Spastic Diplegia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07264166
- **Lead sponsor:** Healing Hope International
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-03-01
- **Primary completion:** 2032-01-01
- **Final completion:** 2032-06-15
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07264166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07264166, "Intranasal AAV9-PHP.eB Gene Therapy in Cerebral Palsy (CP) & Hypoxic Ischemic Encephalopathy (HIE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07264166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*